On Thursday, Soligenix Inc. (NASDAQ:SNGX) opened patient enrollment for its DUS-AUBD-01 Phase 2 study evaluating SGX945 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback